| Formulation |
HLA-DRA protein solution (0.5mg/ml) containing 20mM Tris-HCl buffer (pH 8.0), 0.15M NaCl, 10% glycerol and 1mM DTT. |
| Purity |
Greater than 90% as determined by SDS-PAGE. |
| Description |
HLA-DRA Human Recombinant produced in E.Coli is a single, non-glycosylated polypeptide chain containing 212 amino acids (26-216 a.a) and having a molecular mass of 24.3kDa.HLA-DRA is fused to a 21 amino acid His-tag at N-terminus & purified by proprietary chromatographic techniques. |
| Protein Background |
Major histocompatibility complex, class II, DR alpha (HLA-DRA) belongs to the MHC class II family. HLA-DRA binds peptides derived from antigens which access the endocytic route of antigen presenting cells (APC) and presents them on the cell surface for identification by the CD4 T-cells. The peptide binding cleft accommodates peptides of 10-30 residues. The peptides presented by MHC class II molecules are generated mainly by degradation of proteins which access the endocytic route, where they are processed by lysosomal proteases and other hydrolases. |
| Expression host |
Escherichia Coli. |
| Synonyms |
Major Histocompatibility Complex, Class II, DR Alpha, HLA-DRA1, MHC Class II AntigenDRA, MLRW, Histocompatibility AntigenHLA-DR Alpha, HLAClass II Histocompatibility Antigen, DR Alpha Chain, MHC Cell Surface Glycoprotein, HLA-DRA1. |
| Reagent Appearance |
Sterile Filtered clear solution. |
| Stability |
Store at 4°C if entire vial will be used within 2-4 weeks. Store, frozen at -20°C for longer periods of time.For long term storage it is recommended to add a carrier protein (0.1% HSA or BSA).Please avoid freeze thaw cycles. |
| Amino acid sequence |
MGSSHHHHHH SSGLVPRGSH MIKEEHVIIQ AEFYLNPDQS GEFMFDFDGD EIFHVDMAKK ETVWRLEEFG RFASFEAQGA LANIAVDKAN LEIMTKRSNY TPITNVPPEV TVLTNSPVEL REPNVLICFI DKFTPPVVNV TWLRNGKPVT TGVSETVFLP REDHLFRKFH YLPFLPSTED VYDCRVEHWG LDEPLLKHWE FDAPSPLPET TE |
